Trial · NCT01762046
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Glipizide Response as Measured by Area Over the Glucose Curve Between Time 0 and 240 Minutes According to Genotype | Glipizide and Metformin | Area over the Glucose curve for TCF7L2 CC genotype | 4893.5 | Standard Deviation 2079.4 | mg/dl x time(minutes) |
| Glipizide Response as Measured by Area Over the Glucose Curve Between Time 0 and 240 Minutes According to Genotype | Glipizide and Metformin | Area over the Glucose curve for TCF7L2 CT genotype | 5032.6 | Standard Deviation 2161 | mg/dl x time(minutes) |
| Glipizide Response as Measured by Area Over the Glucose Curve Between Time 0 and 240 Minutes According to Genotype | Glipizide and Metformin | Area over the Glucose curve for TCF7L2 TT Genotype | 6011 | Standard Deviation 3204.8 | mg/dl x time(minutes) |
| Glipizide Response as Measured by Area Under the Insulin Curve Between Time 0 and 240 Minutes According to Genotype | Glipizide and Metformin | Area under the InsulinCurve for TCF7L2 CC genotype | 1141 | Standard Deviation 1910 | mU/L x time (minutes) |
| Glipizide Response as Measured by Area Under the Insulin Curve Between Time 0 and 240 Minutes According to Genotype | Glipizide and Metformin | Area under the InsulinCurve for TCF7L2 CT genotype | 1278 | Standard Deviation 1455 | mU/L x time (minutes) |
| Glipizide Response as Measured by Area Under the Insulin Curve Between Time 0 and 240 Minutes According to Genotype | Glipizide and Metformin | Area under the InsulinCurve for TCF7L2 TT genotype | 1400 | Standard Deviation 1447 | mU/L x time (minutes) |
| Metformin Response - Change in Fasting Glucose From Visit 1 to Visit 2 | Glipizide and Metformin | FastingGlucose V2-FastingGlucose V1 in CC Genotype | -2.1 | Standard Deviation 8.1 | mg/dl |
| Metformin Response - Change in Fasting Glucose From Visit 1 to Visit 2 | Glipizide and Metformin | FastingGlucose V2-FastingGlucose V1 in CT Genotype | -2.2 | Standard Deviation 8.2 | mg/dl |
| Metformin Response - Change in Fasting Glucose From Visit 1 to Visit 2 | Glipizide and Metformin | FastingGlucose V2-FastingGlucose V1 in TT Genotype | -6.1 | Standard Deviation 11 | mg/dl |
| Metformin Response - Change in HOMA-IR From Visit 1 to Visit 2 | Glipizide and Metformin | HOMA-IR Visit 1 - HOMA IR Visit 2 in CC Gentoype | 0.09 | Standard Deviation 1.9 | (mg/dl*uU/ml²) |
| Metformin Response - Change in HOMA-IR From Visit 1 to Visit 2 | Glipizide and Metformin | HOMA-IR Visit 1 - HOMA IR Visit 2 in CT Gentoype | 0.04 | Standard Deviation 1.98 | (mg/dl*uU/ml²) |
| Metformin Response - Change in HOMA-IR From Visit 1 to Visit 2 | Glipizide and Metformin | HOMA-IR Visit 1 - HOMA IR Visit 2 in TT Gentoype | -0.45 | Standard Deviation 0.29 | (mg/dl*uU/ml²) |
| Incretin Levels | Glipizide and Metformin | GLP-1 Total AUC at CC genotype | 1176.2 | Standard Deviation 523 | pmol/L x time (minutes) |
| Incretin Levels | Glipizide and Metformin | GLP-1 Total AUC at CT genotype | 1286.4 | Standard Deviation 540.4 | pmol/L x time (minutes) |
| Incretin Levels | Glipizide and Metformin | GLP-1 Total AUC at TT genotype | 1749.3 | Standard Deviation 1399 | pmol/L x time (minutes) |
| Incretin Levels | Glipizide and Metformin | GLP-1 Active AUC at CC genotype | 879 | Standard Deviation 316.6 | pmol/L x time (minutes) |
| Incretin Levels | Glipizide and Metformin | GLP-1 Active AUC at CT genotype | 1060.8 | Standard Deviation 687.3 | pmol/L x time (minutes) |
| Incretin Levels | Glipizide and Metformin | GLP-1 Active AUC at TT genotype | 1415.7 | Standard Deviation 1681.2 | pmol/L x time (minutes) |
| Incretin Levels | Glipizide and Metformin | GIP AUC at CC genotype | 23523 | Standard Deviation 8227 | pmol/L x time (minutes) |
| Incretin Levels | Glipizide and Metformin | GIP AUC at CT genotype | 24041.2 | Standard Deviation 8126 | pmol/L x time (minutes) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01762046/results